TB-500 and Thymosin Beta-4: Identity, Naming and Research Records

Are TB-500 and thymosin beta-4 the same material?

The name alone cannot answer that question.

1. Full-length mature thymosin beta-4 in the scientific literature. Low and Goldstein chemically characterized a 43-residue peptide with an acetylated N-terminal serine. That paper defines the reference material it studied; it does not define every commercial item later labeled TB-500.
2. The TB-500 product analyzed by Esposito and colleagues. Their 2012 study detected and identified Ac-LKKTETQ, the N-terminally acetylated thymosin beta-4 17-23 fragment, in the particular TB-500 product they examined. The paper does not establish that every product sold under the same label contains that fragment.
3. A current BulkGLP lot record. Match the live product label and physical lot to the original laboratory report. Use the report’s exact identity wording; unless it states a peptide sequence, formula, or explicitly identifies a full-length or fragment material, none of those details can be inferred.

The defensible conclusion is narrow: use the exact identity wording on the applicable report and do not translate it into a sequence-level claim that the report does not make.

What is full-length thymosin beta-4?

The original chemical-characterization study described mature thymosin beta-4 as a 43-amino-acid peptide with an acetylated serine at its N-terminus. Modern protein records may display a 44-residue gene product because they include the initiator methionine; the mature peptide described in the biochemical literature begins after removal of that initiator and is N-terminally acetylated.

This distinction matters when reading sequence databases, mass records, and older biochemical papers. A precursor record and a mature peptide record can display different residue counts without describing two interchangeable commercial products.

Published actin research also needs the material kept explicit. A nuclear-magnetic-resonance study examined thymosin beta-4 binding to monomeric G-actin and reported binding-associated structure across the peptide. Other biochemical work compared full-length thymosin beta-4 with truncated constructs and found that truncation changed measured actin interaction or polymerization behavior under the reported assay conditions. Those findings belong to the exact constructs used in those experiments.

What did the 2012 TB-500 analysis establish?

Esposito and colleagues used high-performance liquid chromatography with high-resolution mass spectrometry to analyze one product labeled TB-500. They identified Ac-LKKTETQ, synthesized the same seven-residue material, and proposed analytical detection methods.

That paper establishes the identity of the material found in its own sample. It is evidence that the TB-500 label has been used for an acetylated thymosin beta-4 fragment. It is not evidence that the label has one universal composition, and it is not a substitute for a current lot report from a different product.

How should BulkGLP’s current record be used?

Start with the TB-500 research material page and follow its current batch-record link. Match the physical vial, product name, lot, and original laboratory report before interpreting identity.

The LC-MS result supplies the laboratory’s identity name for the submitted sample. HPLC-UV purity describes a chromatographic result. Net content addresses measured amount. Endotoxin, microbial, or other screens answer still other method-specific questions when the applicable report includes them. None should be silently converted into a result that the report does not state.

Current lot data changes with inventory. The product page and batch ledger show the active lot, accession, purity, measured content, and sample-specific identity.

How to read TB-500 research without mixing materials

For every paper or analytical record, capture at least five facts before comparing results:

1. The exact material name used by the authors or laboratory.
2. The printed sequence, residue range, or other identity specification, if provided.
3. Any terminal modification, counterion, salt, or formulation stated by the source.
4. The experimental model, assay, concentration, controls, and endpoint.
5. Whether the source studied full-length thymosin beta-4, a defined fragment, a metabolite, a modified analogue, or a commercial sample with its own lot record.

Do not assign findings from a full-length thymosin beta-4 experiment to a seven-residue fragment merely because both sources use related terminology. Do not assign the 2012 fragment finding to a different BulkGLP sample merely because both records include the label TB-500. The identity bridge has to come from the applicable sample documentation.

What an analytical record can and cannot establish

An identity result is not the same as chromatographic purity, measured content, or microbiological testing.

• LC-MS identity compares detected mass-spectral information with the laboratory’s method and reference criteria.
• HPLC-UV purity reports the chromatographic result produced under the stated method; it does not by itself print or prove a complete sequence.
• Net content reports measured amount for the submitted sample and is distinct from an HPLC area percentage.
• Endotoxin and microbial results are method-specific findings at the stated sensitivity or decision threshold.

Use how to read a peptide COA for a method-by-method explanation, and review current and historical batch records before interpreting a product label.

TB-500 inside KLOW, GLOW, or another blend

KLOW, GLOW, and other blends have their own listed components, quantities, and lot-specific analytical records. Those records describe the finished formulation; the terminology above concerns TB-500 and thymosin beta-4 as standalone names.

A shared component label does not prove that two blends contain the same molecular material. Compare each formulation’s current specification and report, then use this terminology reference when a record distinguishes full-length thymosin beta-4, a defined fragment, or another identity.

Frequently asked questions

Is TB-500 always Ac-LKKTETQ?

The reviewed evidence does not support that universal statement. A 2012 paper identified Ac-LKKTETQ in the specific TB-500 product it analyzed. A different sample requires its own identity documentation.

Does an LC-MS identity name by itself prove a full-length sequence?

Not necessarily. Read the applicable report for its printed sequence, molecular identity, method, reference criteria, and any explicit fragment or full-length designation. If it does not state the designation, do not infer it.

Why does the literature call thymosin beta-4 a 43-residue peptide when UniProt shows 44 residues?

The reviewed human protein record includes the initiator methionine in the translated 44-residue sequence. The mature peptide characterized biochemically contains 43 residues after initiator removal and has an acetylated N-terminal serine.

Can full-length thymosin beta-4 actin findings be assigned to a short fragment?

Not automatically. Structural and truncation studies used defined materials and found construct-dependent interactions. A separate material needs its own identity and experimental evidence.

Does a high HPLC-UV percentage resolve the naming question?

No. Chromatographic purity and molecular identity are separate analytical questions. The active report’s exact identity result and the sample-specific documentation remain necessary.

Continue through the research library

• Structural and Binding Peptides
• KPV identity and research reference

Primary and authoritative sources

1. Low TL, Goldstein AL. Chemical characterization of thymosin beta 4. Journal of Biological Chemistry. 1982;257(2):1000-1006. PMID 7054160.
2. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis. 2012;4(9):733-738. DOI 10.1002/dta.1402; PMID 22962027.
3. Domanski M, et al. Coupling of folding and binding of thymosin beta 4 upon interaction with monomeric actin monitored by nuclear magnetic resonance. Journal of Biological Chemistry. 2004;279(22):23637-23645. DOI 10.1074/jbc.M311413200; PMID 15039431.
4. Huff T, Zerzawy D, Hannappel E. Interactions of beta-thymosins, thymosin beta 4-sulfoxide, and N-terminally truncated thymosin beta 4 with actin. European Journal of Biochemistry. 1995;230(2):650-657. DOI 10.1111/j.1432-1033.1995.tb20606.x; PMID 7607239.
5. UniProtKB. Human thymosin beta-4, TMSB4X, P62328. Reviewed protein record used only to explain the translated 44-residue precursor versus the mature 43-residue peptide distinction.